Department of Paediatric Cardiothoracic Transplantation, Freeman Hospital, Newcastle upon Tyne, UK.
J Heart Lung Transplant. 2012 Aug;31(8):791-6. doi: 10.1016/j.healun.2012.03.007. Epub 2012 Jun 12.
Since the introduction of intentional ABO-incompatible (ABOi) cardiac transplantation in infants in the late 1990's, the number of patients listed for and undergoing ABOi transplants has increased. This practice has been shown to lead to a reduction in waiting list mortality and increased utilisation of donor organs with equivalent outcomes to ABO-compatible transplants. Differences in the infant immune system provide a window of opportunity for ABOi transplantation. However it is increasingly clear that older patients and those with significant amounts of blood group antibody specific isohaemagglutinins may also benefit. Newer research is now focussing on longer term outcomes of ABOi transplants - in particular the development of graft accommodation or tolerance. This review assesses the current status of ABO-incompatible cardiac transplantation both in infants and in sensitized and older patients.
自 20 世纪 90 年代末在婴儿中引入有意的 ABO 不相容（ABOi）心脏移植以来，接受 ABOi 移植的患者数量有所增加。这种做法已被证明可以降低候补名单死亡率，并增加了对供体器官的利用，其结果与 ABO 相容的移植相当。婴儿免疫系统的差异为 ABOi 移植提供了机会。然而，越来越明显的是，老年患者和具有大量血型抗体特异性同种凝集素的患者也可能受益。新的研究现在专注于 ABOi 移植的长期结果-特别是移植物适应或耐受的发展。这篇综述评估了 ABO 不相容性心脏移植在婴儿、致敏和老年患者中的现状。
